VAXCYTE, INC. Increase Decrease In Operating Lease Liability
VAXCYTE, INC. (PCVX) reported Increase Decrease In Operating Lease Liability of -$2.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-05
- VAXCYTE, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$851.00K.
- VAXCYTE, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$1.28M, a 108.03% decline year-over-year.
- VAXCYTE, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was $33.14M, a 23.21% decline year-over-year.
- VAXCYTE, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$1.40M, a 158.92% decline year-over-year.
- VAXCYTE, INC. increase decrease in operating lease liability for fiscal 2025 was $46.37M, a 10.71% increase from fiscal 2024.
- VAXCYTE, INC. increase decrease in operating lease liability for fiscal 2024 was $41.89M, a 271.20% increase from fiscal 2023.
- VAXCYTE, INC. increase decrease in operating lease liability for fiscal 2023 was $11.28M, a 880.36% increase from fiscal 2022.
- VAXCYTE, INC. increase decrease in operating lease liability for fiscal 2022 was $1.15M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$851.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$2.14M 10-Q · filed 2026-08-05 | $31.00M derived: sum of 3 quarters · filed 2026-08-05 | $29.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$1.28M 10-Q · filed 2026-05-06 | $31.85M derived: sum of 2 quarters · filed 2026-05-06 | $30.45M derived: sum of 3 quarters · filed 2026-05-06 | $29.09M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $33.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $31.74M derived: sum of 2 quarters · filed 2026-02-24 | $30.37M derived: sum of 3 quarters · filed 2026-08-05 | $46.37M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$2.77M derived: sum of 2 quarters · filed 2026-08-05 | $13.23M 10-Q · filed 2025-11-04 | $56.38M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $14.63M 10-Q · filed 2026-08-05 | $57.79M derived: sum of 3 quarters · filed 2026-08-05 | $60.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $16.00M 10-Q · filed 2026-05-06 | $59.15M derived: sum of 2 quarters · filed 2026-05-06 | $61.53M derived: sum of 3 quarters · filed 2026-05-06 | $59.69M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $43.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $45.53M derived: sum of 2 quarters · filed 2026-02-24 | $43.69M derived: sum of 3 quarters · filed 2026-02-24 | $41.89M 10-K · filed 2026-02-24 |
| 2024-09-30 | $2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $539.00K derived: sum of 2 quarters · filed 2025-11-04 | -$1.26M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | -$1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$3.64M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | -$1.80M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $11.28M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $1.15M 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |